Covid Pioneers Hint Of Cancer Vaccine By 2030
Professors Ugur Sahin and Ozlem Tureci, from Germany, said they have had a “breakthrough” and will keep working, but were hesitant to say they could find a cure for cancer.
The husband and wife said the development and success of the Pfizer/BioNTech vaccine against Covid-19 “gives back to our cancer work”.
The couple, who co-founded BioNTech in Mainz, Germany, in 2008, were interviewed on BBC’s Sunday with Laura Kuenssberg programme and explained how they had worked to pioneer cancer immunotherapies.
Their use of mRNA technology came into its own in the pandemic, and the couple said that experience has helped to spur on their work.
While conventional vaccines are produced using weakened forms of a virus, mRNAs use only a virus’s genetic code.
An mRNA vaccine is injected into the body, where it enters cells and tells them to create antigens which are then recognised by the immune system and prepare it to fight the disease.
Asked when cancer vaccines might be accessed by many patients around the world, Prof Sahin said it could happen “before 2030”.
Prof Tureci told Kuenssberg: “What we have developed over decades for cancer vaccine development has been the tailwind for developing the Covid-19 vaccine, and now the Covid-19 vaccine and our experience in developing it gives back to our cancer work.
“We have learned how to better, faster manufacture vaccines. We have learned in a large number of people how the immune system reacts towards mRNA.”
She said the developments have also helped regulators learn about mRNA vaccines and how to deal with them.
She added: “This will definitely accelerate also our cancer vaccine.”
Taking a positive yet cautious approach, Prof Tureci said: “As scientists we are always hesitant to say we will have a cure for cancer.
“We have a number of breakthroughs, and we will continue to work on them.”
In August, Moderna said it was suing BioNTech and its partner, US pharmaceutical giant Pfizer, for patent infringement over the company’s Covid-19 vaccine.
Asked about that, Prof Sahin said: “Our innovations are original. We have spent 20 years of research in developing this type of treatment and of course we will fight for our intellectual property.”